摘要
目的探讨美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法将2010年6月至2013年9月我院收治的冠心病心力衰竭患者122例按不同治疗方案随机分为试验组（72例，常规治疗＋美托洛尔＋曲美他嗪）和对照组（50例，常规治疗＋美托洛尔），对两组患者治疗效果进行综合比较。结果（1）试验组治疗总有效率达到90．28％，明显高于对照组（76．00％XP〈0．05）（2）经治疗3个月后，试验组患者LEVF、LEVDD、LEVSD以及6rain步行距离明显优于对照组（P〈0．05）。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭效果显著，值得临床推广应用。
Objective To investigate the clinical effects of metoprolol combined with trimetazidine in treating coronary disease with cardiac failure. Methods 122 cases of coronary disease with cardiac failure patients admitted in our hospital from June 2010 to September 2013 were randomly divided into experimental group （72 cases, conventional therapy ＋metoprolol ＋trimetazidine） and control group （50 cases, conventional therapy＋metoprolol）, the efficacy of two groups were compared. Results ① The total efficiency of experimental group （ 90.28% ） was higher than that of control group （ 76.00% ） （P 〈 0.05 ） ;② After 3 months of treatment, the LEVF, LEVDD, LEVSD, 6min walking-distance of experimental group were better than those of control group （P 〈 0.05 ） . Conclusion There is significant effects on metoprolol combined with trimetazidine in treating coronary disease with cardiac failure, which is worthy of clinical use widely.
出处
《国际医药卫生导报》
2014年第5期675-677,共3页
International Medicine and Health Guidance News
关键词
美托洛尔
曲美他嗪
冠心病
心力衰竭
Metoprolol
Trimetazidine
Coronary disease
Cardiac failure
